Kades & Cheifetz LLC Arbutus Biopharma Corp Transaction History
Kades & Cheifetz LLC
- $175 Billion
- Q3 2024
A detailed history of Kades & Cheifetz LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Kades & Cheifetz LLC holds 20,000 shares of ABUS stock, worth $68,400. This represents 0.04% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$68,400
Previous $61.8 Million
24.6%
% of portfolio
0.04%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.6MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$74.2 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$44 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$30.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$28.7 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $513M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...